Different role of MSLN and CA125 co-expression as a prognostic predictor between perihilar and distal bile duct carcinoma
| Autor: | Takazumi Tsunenari, Yoji Kishi, Hideki Ueno, Yasuhiro Takihata, Takahiro Einama, Hironori Tsujimoto, Yoichi Miyata, Takafumi Suzuki, Yoji Yamagishi, Ibuki Fujinuma, Sho Ogata, Kazuki Kobayashi, Naoto Yonamine, Toshimitsu Iwasaki, Eiji Shinto |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Cancer Research medicine.medical_specialty endocrine system diseases MSLN Gastroenterology CA125 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Mesothelin In patient Lymph node biology Oncogene business.industry Cancer Articles Cell cycle medicine.disease Molecular medicine Distal Bile Duct Carcinoma 030104 developmental biology medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis biology.protein cholangiocarcinoma BDC business |
| Zdroj: | Oncology Letters |
| ISSN: | 1792-1082 1792-1074 |
| DOI: | 10.3892/ol.2021.12675 |
| Popis: | Recent studies have suggested that the interaction of mesothelin (MSLN) and cancer antigen 125 (CA125) enhances tumor metastases. The aim of the present study was to clarify the impact of MSLN and CA125 co-expression on the prognosis of patients with extrahepatic bile duct carcinoma (BDC). Tissue samples from patients who underwent surgical resection between 2007 and 2015 for perihilar or distal BDC were immunohistochemically examined. The expression levels of MSLN and CA125 in tumor cells were analyzed. The expression in |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|